%0 Journal Article
%T Comparison of clinical outcome between surgical treatment and particle beam therapy for pelvic bone sarcomas: A retrospective multicenter study in Japan.
%A Takemori T
%A Hara H
%A Kawamoto T
%A Fukase N
%A Sawada R
%A Fujiwara S
%A Fujita I
%A Fujimoto T
%A Morishita M
%A Yahiro S
%A Miyamoto T
%A Saito M
%A Sugaya J
%A Hayashi K
%A Kawashima H
%A Torigoe T
%A Nakamura T
%A Kondo H
%A Wakamatsu T
%A Watanuki M
%A Kito M
%A Tsukushi S
%A Nagano A
%A Outani H
%A Toki S
%A Nishimura S
%A Kobayashi H
%A Watanabe I
%A Demizu Y
%A Sasaki R
%A Fukumoto T
%A Matsumoto T
%A Kuorda R
%A Akisue T
%J J Orthop Sci
%V 0
%N 0
%D 2024 Jul 3
%M 38964957
%F 1.805
%R 10.1016/j.jos.2024.06.007
%X <B>BACKGROUND: </B>Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan.<BR><B>METHODS: </B>A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients).<BR><B>RESULTS: </B>The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis.<BR><B>CONCLUSIONS: </B>The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.